

# Antibacterial Drugs: Market Research Report

<https://marketpublishers.com/r/A95271B8C98EN.html>

Date: April 2010

Pages: 719

Price: US\$ 3,950.00 (Single User License)

ID: A95271B8C98EN

## Abstracts

This report analyzes the worldwide markets for Antibacterial Drugs in US\$ Million by the following drug classes: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Antibacterial Drugs.

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 124 companies including many key and niche players such as Abbott Laboratories, AstraZeneca PLC, Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., and Wyeth Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Cephalosporins

Penicillins

Fluoroquinolones

Macrolides

Other Antibacterial Drugs

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Global Market Outlook

Antibacterial Resistance – A Key Growth Dampener

Antibacterial Resistance Costs High

Patent Expiries Commoditize Antibacterials Market

Patent Expiries of Major Anti-Bacterial Drugs

Generic Competition Intensifies

Cephalosporins Dominate the Anti-bacterials Market

**Table 1.** Worldwide Market for Anti-Bacterials by Major Drug Class (2010): Percentage Share Breakdown for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others (includes corresponding Graph/Chart)

Macrolides and Fluoroquinolones to Grow At a Faster Rate

Major Players and Key Brands

**Table 2.** Select Major Anti-Bacterial Drugs Worldwide (2008 & 2007): Value Sales in US\$ Million for Levaquin/ Floxin, Zosyn/Tazocin, Zyvox, Augmentin, Merrem, Primaxin, Avelox/Avalox, Cravit, Zithromax/Zmax, Cipro/ Ciprobay, Rocephin (includes

corresponding Graph/Chart)

United States Leads the Global Market, Other Regions to Exhibit Faster Growth  
Injectables Gain Traction

## **2.ANTI-BACTERIAL DRUG CLASSES – A REVIEW**

Cephalosporins

Select Major Cephalosporins Worldwide

List of Select Cephalosporin Drugs by Generation

Drug Details of Select Cephalosporins

Omnicef (Abbott Laboratories)

Rocephin (Roche)

Maxipime (Bristol Myers Squibb/Elan)

Zinnat (GlaxoSmithKline)

Spectracef (Cornerstone BioPharma)

Fluoroquinolones

Select Major Fluoroquinolones Worldwide

Drug Details of Select Fluoroquinolones

Levaquin/Floxin/Cravit (Ortho-McNeil-Janssen/ Daiichi Sankyo)

Brand Names of Levofloxacin in Different Regions

Avelox (Bayer)

Ciprofloxacin (Various)

Macrolides

Drug Details of Select Macrolides

Biaxin (Abbott)

Zmax (Pfizer Inc.)

Penicillins

Select Penicillins Worldwide

**Table 3.** Sales of Leading Penicillin Drugs in US\$ Million (2006-2008) (includes corresponding Graph/Chart)

Drug Details of Select Penicillins

Augmentin (GlaxoSmithKline)

Zosyn (Wyeth)

Other Anti-bacterial Drugs

Other Select Anti-bacterials Worldwide

Details of Other Select Anti-bacterial Drugs Worldwide

Zyvox (Pfizer)

Cubicin (Cubist Pharmaceuticals)

Targocid (Sanofi-Aventis/Astellas)

Vancomycin (Eli Lilly)

Carbapenems

Faropenem (Replidyne)

Primaxin (Merck & Co.)

Merrem/Meronem (AstraZeneca)

### **3.AN OVERVIEW OF BACTERIAL INFECTIONS AND TREATMENT**

Bacterial Infections

Types of Bacteria and Bacterial Infections

Overview of Select Bacterial Infections

Pneumonia

Intra-Abdominal Infections

Central Nervous System Infections

Bloodstream Infections

Bone Infections

Surgical Site Infections

Urinary Tract Infections

Urethritis

Hemorrhagic Cystitis

Acute Pyelonephritis

Anti-bacterial Drugs to Combat Against Bacteria

Launch Year of Different Anti-Bacterial Drug Classes

Anti-bacterial Categorization

Classification Based on Action Mechanism

Classification Based on Method of Suppressing Bacterial Growth

Bactericidal Drugs

Bacteriostatic Drugs

Classification Based on Spectra of Activity

Anti-Bacterial Drug Classes and their Uses

Cephalosporins

Treatment

Side Effects

Penicillins

History

Types of Penicillins  
Side Effects  
Fluoroquinolones  
Treatment  
Major Fluoroquinolones Worldwide, Along with Indications  
Side Effects  
Macrolides  
Select Macrolides and its Derivatives by Development Stage (As of 2008)  
Treatment  
Side Effects  
Other Antibacterials  
Aminoglycosides  
Treatment  
Aminoglycosides and Indications  
Side Effects  
Tetracyclines  
Treatment  
Side Effects  
Sulfonamides  
Treatment  
Effects of the Drug  
Mupirocin  
Carbapenems  
Aztreonam  
Glycopeptides  
Vancomycin  
Teicoplanin  
Bacitracin  
Lincosamines  
Polymyxins  
Chloramphenicol  
Limitations of Antibacterial Therapy  
Bacterial Resistance  
Antibacterial-Resistant Bacteria by Type  
Cross-resistance  
Phage Therapy, a Promising Approach for Bacterial Infections  
Treatment and Application of Phage Therapy  
Phages for Antibiotic-Resistant Bacteria  
Companies Involved in Phage Therapy Research

#### **4.PRODUCTS INTRODUCTIONS/APPROVALS/ CLINICAL TRIALS**

Johnson & Johnson Receives Complete Response Letter for Ceftobiprole from US FDA  
Negative Opinion on Ceftobiprole by European CHMP  
Theravance and Astellas Obtains FDA Approval for VIBATIV™ for Treating Complicated Skin and Skin Structure Infections (cSSSI)  
Daiichi Sankyo Company Introduces Cravit® Formulations  
Forest Labs Announces Encouraging Phase III Results of Ceftaroline  
Cubist Pharma Initiates First-In-Human Clinical Trial with CB-183,315  
Basilea Pharmaceutica Announces New Research Results for BAL30072 in Multi-Resistant Gram- Negative Bacteria  
Galderma Laboratories Launches Epiduo™ Gel for Acne Treatment  
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug  
US FDA Asks Arpida to Secure Additional Data for Iclaprim  
MiddleBrook Obtains FDA Approval for MOXATAG™  
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin  
Watson Pharma Introduces Biaxin XL's Generic Version  
Taisho Toyama Pharmaceutical Rolls Out Zosyn® to Treat Severe Bacterial Infections  
GSK Launches ALTARGO® in the UK  
Daiichi Obtains Approval for Gracevit®  
New Research Backs LEVAQUIN Use in CAP Treatment in Concordance with Guidelines  
FDA Instructs Targanta to Conduct Additional Oritavancin Trials  
J&J's Doribax Obtains FDA Approval for Urinary Tract and Intra-abdominal Infections  
APL Receives FDA Approval for Cefpodoxime Proxetil  
Toyama Launches New Garenoxacin Quinolone Antibiotic  
Wockhardt to Introduce Cefprozil Tablets in the US  
MSD India Launches Invanza in India  
Macrolide Antibiotic Developed in the US  
GSK Obtains EC Approval for Altargo® in Treating Skin Infections

#### **5.RECENT INDUSTRY ACTIVITY**

Pfizer Indicts Teva for Zyvox Patent Infringement  
Beactica and Cubist Sign Agreement to Develop Advanced Anti-Bacterials  
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin  
Forest Laboratories Collaborates with AstraZeneca to Co-Develop Ceftaroline  
TB Alliance Enters into Multiple Deals for TB Drug Discovery

Kemin Industries Acquires Amalyte Pharmaceuticals  
Forma Therapeutics Sign Deal with Cubist to Make Antibacterial Drugs  
Lee's Pharmaceutical Holdings Acquires Rights to Oral Antibacterial Drug  
Anacor Pharmaceuticals Collaborates with TB Alliance  
Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin  
Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery  
Abbott Acquires Ibis Biosciences  
Elder and Strides on Expansion Mode  
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma  
Akorn Signs Agreement with Eli Lilly and Company  
NovaBay Inks Agreement with Medical University of Innsbruck  
Tibotec Collaborates with Global Alliance for TB Drug Development  
Sandoz Introduces Generic Maxipime®  
Merck and Ranbaxy to Launch Anti-Bacterial and Anti-Fungal Drugs  
Wyeth Receives an Approvable Letter from US FDA for TYGACIL®  
Mylan Receives FDA Approval for Linezolid 600 mg Tablets  
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden  
MiddleBrook Obtains NDA Approval for MOXATAG™  
ULL Establishes New Antibiotics Unit in Himachal Pradesh  
Biocat to Expand Presence in the Indian Market  
Novartis to Acquire Protez  
Orchid Signs Licensing Agreement with Merck  
Forest and Novoxel Sign Licensing Agreement  
Sanofi-aventis Collaborates with Novozymes  
AstraZeneca Acquires Arrow Therapeutics  
Cubist Submits INDs for CB-182,804 and CB-183,315  
GlaxoSmithKline Enters into Strategic Alliance with Mpex Pharmaceuticals to Develop Novel Drugs to treat Bacterial Diseases  
Advanced Life Sciences and Wyeth Pharmaceuticals Sign Marketing Deal for Commercialization of Cethromycin in Asia Pacific  
GlaxoSmithKline Receives FDA Approval for Altabax  
GSK and Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals  
Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®  
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU  
Cubist Gains Approval for CUBICIN in Taiwan and South Korea  
Cethromycin Achieves FDA's Orphan Drug Designation  
GSK Receives Approval for ALTARGO® in Europe  
sanofi-aventis Updates Prescription Information for Ketek in the US

## 6.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)  
AstraZeneca PLC (UK)  
Bayer HealthCare AG (Germany)  
Bristol-Myers Squibb Co. (USA)  
Cubist Pharmaceuticals, Inc. (USA)  
Daiichi Sankyo Company, Ltd. (Japan)  
GlaxoSmithKline Plc. (UK)  
Johnson & Johnson (USA)  
Pfizer, Inc. (US)  
Wyeth Pharmaceuticals, Inc. (US)

## 7.GLOBAL MARKET PERSPECTIVE

**Table 4.** World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 5.** World 10-Year Perspective for Antibacterial Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

**Table 6.** World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 7.** World 10-Year Perspective for Cephalosporins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

**Table 8.** World Recent Past, Current & Future Analysis for Penicillins by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)



**Table 9.** World 10-Year Perspective for Penicillins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

**Table 10.** World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 11.** World 10-Year Perspective for Fluoroquinolones by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

**Table 12.** World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 13.** World 10-Year Perspective for Macrolides by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

**Table 14.** World Recent Past, Current & Future Analysis for Other Anti-bacterial Drugs by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 15.** World 10-Year Perspective for Other Anti-bacterial Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

### **III. MARKET**

#### **1. THE UNITED STATES**

##### **A. MARKET ANALYSIS**

Current & Future Analysis  
Products Approvals/Launches/Clinical Trials

Strategic Corporate Developments  
Key Players

## **B. MARKET ANALYTICS**

**Table 16.** US Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 17.** US 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

## **2.EUROPE**

### **A. MARKET ANALYSIS**

Current and Future Analysis  
Strategic Corporate Developments

### **B. MARKET ANALYTICS**

**Table 18.** European Recent Past, Current & Future Analysis for Antibacterial Drugs by Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 19.** European 10-Year Perspective for Antibacterial Drugs by Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

**Table 20.** European Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class- Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 21.** European 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

## **2A.FRANCE**

### **A. MARKET ANALYSIS**

Antibiotics Use Takes A Dip, As Regulatory Authorities' Efforts Pays Off

### **B. MARKET ANALYTICS**

**Table 22.** French Recent Past, Current & Future Analysis for Antibacterial Drugs- Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2B.GERMANY**

### **A. MARKET ANALYSIS**

Key Player

Bayer HealthCare AG

### **B. MARKET ANALYTICS**

**Table 23.** German Recent Past, Current & Future Analysis for Antibacterial Drugs – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2C.ITALY**

Market Analysis

**Table 24.** Italian Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart)

## **2D.THE UNITED KINGDOM**

### **A. MARKET ANALYSIS**

Infectious Diseases – A Quick Primer  
Research and Development of New Anti-Infectives  
Products Introduction  
Strategic Corporate Developments  
Key Players

### **B. MARKET ANALYTICS**

**Table 25.** UK Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2E.SPAIN**

Market Analysis

**Table 26.** Spanish Recent Past, Current & Future Analysis for Antibacterial Drugs- Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## **2F.REST OF EUROPE**

### **A. MARKET ANALYSIS**

Strategic Corporate Development  
Key Player  
F. Hoffmann-La Roche, Ltd. (Switzerland)

### **B. MARKET ANALYTICS**

**Table 27.** Rest of Europe Recent Past Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

### **3.ASIA-PACIFIC**

#### **A. MARKET ANALYSIS**

Focus on Select Regional Markets

China

Carbapenem Antibiotics Hold Great Potential

India

Injectable Antibiotics Demonstrate Robust Growth

New Initiative to Develop Novel Antibiotic Molecules

Products Introductions/Developments

Strategic Corporate Developments

Key Players

#### **B. MARKET ANALYTICS**

**Table 28.** Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 29.** Asia-Pacific 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

### **4.REST OF WORLD**

#### **A. MARKET ANALYSIS**

Strategic Corporate Developments

#### **B. MARKET ANALYTICS**

**Table 30.** Rest of World Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 31.** Rest of World 10-Year Perspective for Antibacterial Drugs by Drug Class – Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled:124 (including Divisions/Subsidiaries - 127)

Region/CountryPlayers

The United States26

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

## I would like to order

Product name: Antibacterial Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/A95271B8C98EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A95271B8C98EN.html>